XOSPATA 40 mg, film-coated tablet 84 tablets
Active ingredients: Gilteritinib fumarate, Gilteritinib
Commercialized according to BDPMDispensing in France: Prescription only
Film-coated tablet84 tabletsorale
No current ANSM shortage notice is included
Package details
Original BDPM fields are shown in French.
- Official name
- XOSPATA 40 mg, comprimé pelliculé
- Pharmaceutical form
- comprimé pelliculé
- Route of administration
- orale
- Presentation description
- 4 plaquette(s) OPA : polyamide orienté aluminium PVC-Aluminium de 21 comprimé(s)
- Marketing authorisation holder
- ASTELLAS PHARMA EUROPE (PAYS-BAS)
- Reimbursement according to BDPM
- 100%
- Approval for use in healthcare institutions
- oui
- Commercialization declaration date
- 9 Jan 2020
- Prescription and dispensing conditions
- Prescription only
- List I: prescription-only medicine
- Requires special monitoring during treatment
- Prescribed by a hospital doctor
- Prescribed by specialists only
- Enhanced ANSM monitoring
- No
BDPM identifiers
CIS
66204797CIP73019078CIP133400930190784Composition in BDPM
| Component | Amount per unit | Source type |
|---|---|---|
| FUMARATE DE GILTÉRITINIBcomprimé | — | SA |
| GILTÉRITINIBcomprimé | 40 mg · un comprimé | FT |
Information is based on BDPM data and is for reference only. Consult a doctor before use.
Similar medicines
Similar medicines are listed using the official BDPM catalog. Availability must be checked separately. Consult a doctor or pharmacist before switching medicines.
The current BDPM data does not list similar medicines for this product.